Skandinaviska Enskilda Banken AB publ Sells 146 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Skandinaviska Enskilda Banken AB publ reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,808 shares of the biopharmaceutical company’s stock after selling 146 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned 0.07% of Regeneron Pharmaceuticals worth $77,580,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. AE Wealth Management LLC grew its position in shares of Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 89 shares during the period. Simplify Asset Management Inc. lifted its stake in Regeneron Pharmaceuticals by 108.5% in the second quarter. Simplify Asset Management Inc. now owns 6,360 shares of the biopharmaceutical company’s stock valued at $6,685,000 after buying an additional 3,310 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Regeneron Pharmaceuticals by 7.6% in the second quarter. Canada Pension Plan Investment Board now owns 134,762 shares of the biopharmaceutical company’s stock valued at $141,639,000 after buying an additional 9,472 shares during the period. Benjamin F. Edwards & Company Inc. increased its position in shares of Regeneron Pharmaceuticals by 25.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,980 shares of the biopharmaceutical company’s stock worth $3,132,000 after acquiring an additional 612 shares in the last quarter. Finally, Trust Investment Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $202,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the transaction, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at $13,540,179.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The disclosure for this sale can be found here. In the last three months, insiders sold 10,026 shares of company stock worth $11,498,705. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $1,150.19 on Friday. The company has a market cap of $126.80 billion, a PE ratio of 33.98, a price-to-earnings-growth ratio of 3.93 and a beta of 0.12. The firm has a 50-day moving average of $1,130.85 and a 200-day moving average of $1,030.53. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company posted $8.79 earnings per share. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on REGN. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,111.30.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.